Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Impact of OMT on the Symptoms of Dysmenorrhea

23 september 2026 bijgewerkt door: David Redding, Western University of Health Sciences

Assessing the Impact of Osteopathic Manipulative Treatment on Dysmenorrhea

This pilot study will span two months per participant and include a baseline evaluation, a control period, the treatment itself, and an after-treatment evaluation. After getting informed consent, participants will be asked to fill out surveys about their menstrual cycles and health histories, including pain levels, timing, and the types and length of symptoms they may have. Participants will then go through a month control period where they will have their cycle without any osteopathic manipulative treatment (OMT) being given, followed by a standard osteopathic exam. They will be asked to fill out all surveys again at this time. They will then go through OMT 3-7 days before their next period. After their second cycle, they will complete a final survey. Participants' pain and symptoms will be assessed at each time point by comparing survey responses and checking for improvement. The goal of this study is to see whether osteopathic manipulative treatment reduces pain and eases symptoms, and whether this approach is practical for future studies.

Studie Overzicht

Toestand

Werving

Conditie

Gedetailleerde beschrijving

This prospective longitudinal pilot study will last two months per subject. It uses a within-subjects design (pre-post comparison with an internal control phase). The study includes a pre-intervention assessment, a control phase, the intervention, and a post-intervention assessment. After obtaining informed consent, subjects will complete an initial baseline survey assessing menstrual cycle characteristics, including pain intensity (0-10 scale), duration, symptom types, and frequency.

The baseline survey will include screening questions regarding subjects' medical history to identify conditions associated with secondary dysmenorrhea (e.g., endometriosis, PCOS, thyroid disorders, or other relevant gynecologic conditions). These questions will be used to ensure that participants do not meet any exclusion criteria indicating secondary dysmenorrhea. Subjects will also be asked to confirm that they are not currently receiving other therapeutic interventions (such as OMT, physical therapy, or other manual treatments) for dysmenorrhea during the study period. This is intended to ensure that the study evaluates the effects of a single standardized OMT intervention without interference from concurrent treatments and to establish an accurate baseline comparison between the control and intervention menstrual cycles.

Following completion of the baseline survey of menstrual cycle characteristics, subjects will enter a control period consisting of one complete menstrual cycle without osteopathic manipulative treatment (OMT). During the control period, participants will complete an initial survey before menses, followed by a post-menstrual survey at the end of this untreated cycle. Subjects who report new exclusion criteria during the study period will be withdrawn from participation.

Following the control phase, subjects will undergo a standardized osteopathic structural exam, followed by OMT, approximately 3 to 7 days before the menstrual cycle. After the intervention and after the completion of menses, subjects will complete a post-menstrual exit survey. Upon completion of the study, all surveys will be compared, and changes in the data will be analyzed.

The structural exam and OMT will include: A normal, osteopathic structural exam of the lumbar, pelvis, and sacrum (assessing for lumbar spinal asymmetry, tenderness, and hypertonicity of paraspinal muscles, pelvic landmarks; ASIS, PSIS, pubic symphysis, sacral sulcus depth, and Inferior lateral angles of the sacrum). OMT will include soft tissue of the lumbar spine, articulatory and muscle energy techniques, and possible HVLA (quick adjustments of dysfunctional joints).

Data will be de-identified and analyzed using descriptive statistics and within-subject comparisons (paired t-tests or nonparametric equivalents) to assess changes in pain and symptom scores between the control and intervention phases. The primary outcomes will include reductions in average pain intensity and symptom burden, while secondary outcomes will assess analgesic use. Results will inform feasibility and potential efficacy for future larger-scale studies.

Descriptive statistics will include means, standard deviations, medians, and frequencies for all variables. Paired t-tests or, if necessary, the Wilcoxon signed-rank test will be used to compare control and OMT intervention phase pain and symptom scores. Repeated-measures analysis (RM-ANOVA or Friedman test) will be used to examine time-based trends across the baseline, control phase, intervention phase, and post-intervention point. We will also analyze feasibility metrics, including completion rates, survey adherence, and treatment attendance.

Studietype

Ingrijpend

Inschrijving (Geschat)

30

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • California
      • Pomona, California, Verenigde Staten, 91766-1854
        • Werving
        • Western University of Health Sciences

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

20 jaar tot 51 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Female Western University of Health Sciences students, faculty, or staff who experience dysmenorrhea symptoms.

Exclusion Criteria:

  • Individuals who are pregnant or breastfeeding.
  • Individuals under the age of 20 and over the age of 51.
  • Individuals with a history of endometriosis or PCOS.
  • Individuals with a history of thyroid conditions.
  • Individuals who change or plan ot change birth control during the course of the study.
  • Individuals receiving outside OMT or physical therapy treatment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Control time period vs. OMT Intervention period

This single-arm study consists of participants undergoing a 1-month control period with no intervention prior to their menstrual cycle, during which they don't alter their daily lives. This is followed by a second month in which they undergo a menstrual cycle with OMT intervention 3-7 days before menstruation.

Manual applied therapeutic techniques to correct somatic dysfunction and asymmetry of the lumbar and cervical pelvis and sacrum. This includes soft-tissue, articulatory, muscle energy, myofascial release, and High-Velocity Low-Amplitude (HVLA).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Menstrual Pain Numeric Scale Rating (NRS)
Tijdsspanne: Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).

The NRS is a widely used and validated tool for measuring menstrual pain in subjects participating in clinical trials. This self-reported pain scale ranges from 0 to 10. A score of zero indicates no pain, and a score of 10 indicates the worst possible pain.

Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Premenstrual Syndrome Scale (PMSS) Scores
Tijdsspanne: Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).

The PMSS (Premenstrual Syndrome Symptom Scale) is a self-assessment questionnaire consisting of 40 items designed to evaluate the severity of physiological, psychological, and behavioral symptoms associated with Premenstrual Syndrome (PMS). It employs a 5-point Likert scale to score symptom severity, where "never" is 1, "rarely" 2, "sometimes" 3, "very often" 4, and "always" 5.

The total score can range from a minimum of 40 points to a maximum of 220 points. A score of 80 points or higher indicates the presence of PMS, with higher scores reflecting greater symptom severity.

Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).
Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea (WaLIDD) Score
Tijdsspanne: Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).

The WaLIDD score is a 4-item questionnaire designed to assess the severity of dysmenorrhea. It consists of the following components:

  1. Number of Anatomical Pain Locations

    • "0" = no part of the body
    • "1" = pain in 1 site
    • "2" = pain in 2-3 sites
    • "3" = pain in 4 sites
  2. Wong-Baker Pain Intensity Rating

    • "0" = does not hurt
    • "1" = hurts a little bit
    • "2" = hurts a little more or even more
    • "3" = hurts a lot or hurts worst
  3. Number of Painful Days During the Menstrual Period

    • "0" = 0 days
    • "1" = 1-2 days
    • "2" = 3-4 days
    • "3" = 5+ days
  4. Frequency of Pain that Prevents Activities

    • "0" = none
    • "1" = almost none
    • "2" = almost always
    • "3" = always Each item scores between 0 and 3, resulting in a total score ranging from 0 to 12. A higher score indicates a greater degree of dysmenorrhea. Specifically, a score of 0 suggests no dysmenorrhea, 1-4 indicates mild, 5-7 indicates moderate, and 7-12 indicates severe dysmenorrhea.
Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).
Modified Quantitative Analgesic Questionnaire (QAQ)
Tijdsspanne: Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).

The Quantitative Analgesic Questionnaire is a tool that was initially designed to document and quantify patient-reported medication use in settings of chronic pain. The QAQ was found to be a valuable tool in quantifying medication regimen and tracking changes over time.

For this study, the QAQ was adapted to include only Section A, with wording modified to reflect analgesic use for dysmenorrhea. Sections B and C were excluded because they assess medications not typically used in the management of dysmenorrhea.

Participants will report the type, dose, frequency, and duration of analgesic medications taken. For frequency quantification, they will be asked how many days prior to and during their period they used medication or non-medication methods, on a scale of 1 to 10 days, with higher values indicating longer use of methods to tolerate symptoms prior to periods. This will allow for the quantification of medication use and the evaluation of differences in analgesic consumption.

Baseline, at the end of Cycle 1 (each cycle is 28 days), and at the end of Cycle 2 (an additional 28 days).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: David Redding, DO, Western University of Health Sciences

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 april 2026

Primaire voltooiing (Geschat)

31 december 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

10 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

23 september 2026

Eerst geplaatst (Werkelijk)

30 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 september 2026

Laatste update ingediend die voldeed aan QC-criteria

23 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

All components of this study will be made available to other researchers if desired. Please reach out to the PI with requests.

IPD-tijdsbestek voor delen

After the study is published.

IPD-toegangscriteria voor delen

All interested research professionals.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren